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Abstract In patients with stable coronary artery disease
(CAD) without overt heart failure, ACE inhibitors are
among the most commonly used drugs as these agents have
been proven effective in reducing the risk of cardiovascular
events. Considerable individual variations in the blood
pressure response to ACE inhibitors are observed and as
such heterogeneity in clinical treatment effect would be
likely as well. Assessing the consistency of treatment
benefit is essential for the rational and cost-effective
prescription of ACE inhibitors. Information on heterogene-
ities in treatment effect between subgroups of patients could
be used to develop an evidence-based guidance for the
installation of ACE-inhibitor therapy. Obviously, therapy
should only be applied in those patients who most likely
will benefit. Attempts to develop such treatment guidance
by using clinical characteristics have been unsuccessful. No
heterogeneity in risk reduction by ACE inhibitors has been
observed in relation to relevant clinical characteristics. A
new approach to such ‘guided-therapy’ could be to
integrate more patient-specific characteristics such as the
patients’ genetic information. If proven feasible, pharma-
cogenetic profiling could optimise patients’ benefit of
treatment and reduce unnecessary treatment of patients.
Cardiovascular pharmacogenetic research of ACE inhib-
itors in coronary artery disease patients is in a formative
stage and studies are limited. ThePERGENEstudyisa large
pharmacogenetic substudy of the EUROPA trial, aimed to
assess the achievability of pharmacogenetic profiling. We
provide an overview of the main results of the PERGENE
study in terms of the genetic determinants of treatment benefit
and blood pressure response. The main results of the
PERGENE study show a pharmacogenetic profile related to
the treatmentbenefitofperindoprilidentifyingrespondersand
non-responders to treatment.
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The angiotensin-converting enzyme (ACE) inhibitors compet-
itively block the conversion of angiotensin-I (AT-1) into
angiotensin-II (AT-II). This blockade results in a decrease in
circulatingandlocal levels of AT-II,therebyinhibitingthe main
effects of AT-II which are arteriolar vasoconstriction and water
and salt retention. ACE inhibitors decrease the transformation
of bradykinin in inactive peptides, thereby increasing the levels
of bradykinin [1, 2]. The increase in levels of bradykinin
leads to a higher release of nitric oxide and prostaglandins
with vasodilatory effects on vessel walls [2, 3].
The efficacy of ACE inhibitors has been demonstrated
by several large clinical trials in a broad variety of patients
at different levels of risk [4–11]. Nowadays, the use of ACE
inhibitors is recommended in guidelines on the manage-
ment of hypertension, stable coronary artery disease
(CAD), myocardial infarction (MI), and heart failure, and
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prescribed drugs in these patient groups [12–14].
This review is primarily focused on patients with stable
CAD and the ACE inhibitor perindopril as studied in the
EUROPA trial andits substudy the PERGENE study [10, 15].
The EUROPA trial
The EURopean trial On reduction of cardiac events with
Perindopril in patients with stable coronary Artery disease
(EUROPA) studied the ACE inhibitor perindopril in a
population with stable coronary artery disease with pre-
served left ventricular function [10]. In EUROPA, 12,218
patients were randomly assigned perindopril 8 mg once
daily (n=6110) or matching placebo (n=6108). The
primary endpoint was a composite of cardiovascular
mortality, myocardial infarction, or cardiac arrest. During
a mean follow-up of 4.2 years, perindopril was associated
with a reduction in the incidence of the primary endpoint
from 9.9% in placebo to 8.0% in perindopril-treated
patients, which yielded a 20.5% relative risk reduction
(HR 0.80; 95% CI 0.71–0.91) (Fig. 1)[ 10].
One would like to guide such prolonged prophylactic
treatment to only those patients who will encounter
treatment benefit. Heterogeneity in the clinical treatment
effect of ACE inhibitors might be used to guide ACE
inhibitor therapy only to those patients most likely to
benefit from such therapy and, by doing so, the overall
clinical efficacy could be increased (lower number needed
to treat). Tailored ACE inhibitor therapy will improve
patient benefit, and reduce unnecessary healthcare costs and
side effects. Several analyses have been performed to test
the consistency of the treatment benefit of ACE inhibitors
among patient subgroups based on clinical characteristics
which are discussed below [16–20].
Guiding ACE inhibitor treatment based on clinical
characteristics
Using the EUROPA trial data, a risk model based on
baseline clinical characteristics related to the primary
endpoint was developed to predict outcome in these
patients depending on the patient’s baseline risk [17].
However, the treatment benefit of perindopril was consis-
tent across different risk categories and therefore not
modified by the level of baseline risk. Another post-hoc
analysis of the EUROPA study demonstrated that renal
insufficiency does not modify the treatment benefit of ACE
inhibitors [18, 19]. Finally, in a recent meta-analysis which
combined several trials investigating the ACE inhibitor
perindopril in 29,463 patient with vascular disease (stable
CAD, cerebrovascular disease and diabetes), a consistent
treatment effect of ACE inhibitor based regimens was
demonstrated, independent of clinical characteristics or
baseline blood pressure levels (Fig. 2)[ 20]. We have
concluded that, although many studies have been per-
formed to test the heterogeneity of treatment benefit of
ACE inhibitors in patients with stable CAD, based on these
studies it does not appear to be feasible to guide ACE
inhibitor therapy to specific subgroups of patients based
only on clinical characteristics.
New approaches to guiding ACE inhibitor therapy
We used more patient-specific characteristics such as patients’
genetic information (DNA). Pharmacogenetics is aimed to
understand why some drugs work better for some people than
others and why some people are more likely to experience side
effects. If genetic factors are indeed related to drug response,
pharmacogenetic profiling might be a new way to reach
significant advances in individualised cardiovascular medicine.
Currently, pharmacogenetic research of ACE inhibitors is
rare. In general, it is expected that the response of a patient to
therapy can be influenced by several types of genetic factors:
1) Genetic factors causing differences in drug absorption and
metabolic clearance are highly relevant (pharmacokinetics);
however; this is still a relatively unexplored field for ACE
inhibitors. 2) Genetic factors within the direct pharmacody-
namic pathway that is affected by the ACE inhibitors, the
renin–angiotensin–aldosterone system (RAAS), and bradyki-
nin gene pathways are likely to affect the clinical efficacy of
ACE inhibitors, including receptors and signal transduction
molecules. Also, variations within genes of the RAAS and
related systems may influence atherosclerosis and thereby
inherent differences in the susceptibility to the antiathero-
sclerotic properties of ACE inhibitors [21, 22].
The vast majority of prior studies focused on only one or
two polymorphisms, the angiotensin-converting enzyme
(ACE) I/D polymorphism and the M235T polymorphism in
the angiotensinogen (AGT) gene. This is a severe limitation
and does not justify the complexity of the renin-angiotensin
system. Because of limited study sample size and power,
results have been inconsistent. Limited prior research with
ACE inhibitors in stable CAD has been performed at large-
scale or in a randomised trial setting.
Concept of pharmacogenetic research to individualise
medicine
The concept of pharmacogenetic research to individualise
medicine is emerging rapidly and is clinically highly
relevant. Several successes of this approach have recently
Neth Heart J (2012) 20:24–32 25been demonstrated for different cardiovascular agents, such
as the activation of clopidogrel [23, 24] and the risk of
rhabdomyolysis associated with statin therapy [25]. Current
pharmacogenetic data are often obtained from observational
cohort studies or cross-sectional data. The overall objective
of CVD pharmacogenetics is to construct a genetic profile
which enables the doctor to predict the patient’s benefit of
treatment in advance, before subscription or during sub-
scription when patients response is different from expected.
The PERGENE study
The PERindopril GENEtic association study (PERGENE) is a
pharmacogeneticsubstudyofthemainEUROPAtrial[15]. The
PERGENE study aims to assess the practicability of
pharmacogenetic profiling of treatment benefit of ACE
inhibitors in patients with stable CAD for reasons addressed
above. We hypothesised that genetic polymorphism in the
RAAS and kininogen–kallikrein–bradykinin pathways influ-
ences the treatment benefit of ACE inhibitors in patients with
stable CAD. The main outcome measure of PERGENE was
the interaction between genetic factors and treatment effect of
ACE inhibitors during follow-up. Secondary endpoint was the
relation between the genetic determinants and blood pressure
and blood pressure reduction to ACE inhibitor therapy [15].
Study design
Exact details on the study design, SNP selection procedure
and statistical analysis can be found elsewhere [15]. In brief,
the PERGENE study investigates whether common genetic
variation is related to the risk of future events and modifies
the treatment effect of perindopril. Written informed consent
for performing genetic association analyses was obtained
from all patients. A DNA bio-bank was established within
the EUROPA trial (at the beginning of the EUROPA study)
for the PERGENE substudy [15]. Blood samples were
received from 10,060 patients and DNA was successfully
isolated from 9454 patients using an automated isolation
process (Hamilton NV, USA). Twelve candidate genes within
Fig. 1 Treatment benefit of perindopril on primary endpoint and
selected secondary endpoints in the EUROPA trial. MI=myocardial
infarction. UA=unstable angina. Size of squares proportional to
number of patients in that group. Dashed line indicates overall relative
risk reduction. Adapted with permission (Lancet 2003; 362: 782–88)
26 Neth Heart J (2012) 20:24–32the direct pharmacodynamic pathway of ACE inhibitors, the
RAAS and bradykinin systems, were selected for this
analysis (Fig. 3). To cover common variation in these 12
candidate genes comprehensively, haplotype-tagging SNPs
(ht-SNP) were selected based on the linkage disequilibrium
(LD) structure as provided by the public databases of
HapMap, PARC, and SeattleSNPs.
The treatment effect of perindopril was defined as the
reduction in the event rate of the primary endpoint of the
EUROPA trial compared between genotype strata for each
SNP. Genotype-treatment interactions were assessed with
multivariate Cox proportional hazards regression models.
Multipletestingcorrectionsoftreatmentinteractionterms,and
estimation of empirical P-values, were implemented using
Monte Carlo permutation analysis (10,000 permutations) on
a per-gene basis.
Results of the PERGENE study
Pharmacogenetic determinants of clinical treatment effect
of ACE inhibitors
In unadjusted analysis, 7 single nucleotide polymorphisms
in 4 different candidate genes were significantly associated
with the treatment effect of perindopril. In multivariate
permutation analysis, 3 of these SNPs, located in the AT1
receptor and BK1 receptor genes, remained significant
modifiers of the treatment benefit of perindopril [26].
In the BK1 receptor gene, rs12050217 was a strong
modifier of the treatment benefit of perindopril as presented
in Fig. 4. Additionally, in the AT1 receptor gene, rs275651
and rs5182 significantly modified the treatment benefit of
perindopril. Genetic determinants of treatment benefit of
perindopril have not been demonstrated previously [26].
We constructed a pharmacogenetic risk score by com-
bining the unfavourable alleles of the treatment effect
modifying SNPs (Fig. 5)[ 26]. Unfavourable alleles were
associated with diminished treatment effect as observed in
the overall study group. The pharmacogenetic risk score
demonstrated a decrease in the level of treatment benefit of
perindopril with an increasing number of unfavourable
alleles. In patients with no unfavourable alleles, a much
more pronounced treatment benefit was observed as
compared with the overall study result (which yielded a
20% relative risk reduction). By combining pharmacoge-
netic risk scores, we observed that the treatment benefit was
concentrated in about 3 out of 4 of the patients and absent
in 1 out of 4 of the patients [26]. This is the first time that
subgroups of responders and non-responders to ACE
inhibitor treatment have been identified. An interaction
effect of similar direction and magnitude was observed in
Fig. 2 Consistency of treatment
benefit of perindopril in
patients with vascular disease
(meta-analysis of ADVANCE,
PROGRESS, EUROPA individ-
ual data). MI=myocardial infac-
tion, CVA=cerebrovascular
accident, TIA=transient ischae-
mic attack. Adapted with
permission from Brugts JJ et al.
Eur Heart J 2009; 30,
1385–1394
Neth Heart J (2012) 20:24–32 27an initial confirmatory analysis of 1051 patients with
cerebrovascular disease from the PROGRESS trial [26].
In the patients who were identified as responders and
non-responders with pharmacogenetic profiling, no differ-
ences in clinical characteristics were observed in PER-
GENE [26]. Also intermediate phenotypes such as blood
pressure and blood pressure reduction levels were compa-
rable between responders and non-responders [26]. Thus,
the observed treatment interaction cannot be explained by
clinical differences between the genotypes but can only be
prescribed to the net genetic difference between patients.
RAAS genes in relation to hypertension and blood pressure
reduction to ACE inhibitors
As hypertension is a strong intermediate phenotype of
CAD, we investigated whether genetic variations in the
Fig. 5 Treatment effect according to the pharmacogenetic profile
categories. Responders=<3 unfavourable alleles, non-responders ≥3
unfavourable alleles. Adapted with permission from Brugts JJ, et al.
Eur Heart J. 2010 Aug;31(15):1854–64
Fig. 4 Treatment effect modifying SNPs in PERGENE. 1/1=homozy-
gous common allele, ½=heterozygous, 2/2=homozygous common allele.
Percentages correspond to the number of patients within each group
according to genotype. The X-axis corresponds to the hazard ratio and
95% CI estimates and Y-axis to genotype category. Adapted with
permissionfromBrugtsJJ,etal.Eur Heart J. 2010 Aug;31(15):1854–64
Fig. 3 Selected candidate genes in the renin–angiotensin–aldosterone
system and bradykinin pathways. AGT angiotensinogen, REN renin,
ACE angiotensin-converting enzyme, AGTR1 angiotensin II receptor
type 1, AGTR2 angiotensin II receptor type 2, CYP11B aldosteron
synthase, KLK kallikrein, KNG kininogen, BDKRB1 bradykinin
receptor type 1, BDKRB2 bradykinin receptor type 2, eNOS3 nitric
oxide synthase. Adapted with permission from Brugts JJ et al.
Cardiovasc Drugs Ther 2009;23:171–181
28 Neth Heart J (2012) 20:24–32cascade of RAAS/bradykinin system genes are involved in
blood pressure and whether such genetic variations deter-
mine the BP response to ACE inhibitor therapy which is
highly variable between patients [27]. A differential BP
effect determined by genetic factors may give insight into
their clinical effects.
The PERGENE study demonstrated that the genetic
variants in the ACE, angiotensinogen and prorenin gene were
important determinants of hypertension at baseline. These
genetic determinants of hypertension in the RAAS system
were also observed in the two replication cohorts of the
PROGRESS trial (patients with cerebrovascular disease) and
ERGOstudy(relativelyhealthyelderlysubjects)[27]( F i g .6).
However, the blood pressure response to the ACE inhibitor
perindopril was not modified by the genetic polymorphisms
in the RAAS or bradykinin pathway.
These findings are consistent with prior subgroup
analyses on blood pressure and BP reduction by ACE
inhibitor therapy demonstrating that the clinical benefits are
independent of blood pressure and the amount of BP
reduction [20, 28, 29].
To strengthen our results, the Blood Pressure Lowering
Treatment Trialists’ Collaboration (BPLTTC) consortium
studied the blood pressure dependent and independent
effects of ACE inhibitors in 146,838 patients and confirmed
that a beneficial effect up and above blood pressure
reduction is present [29]. Substudies of EUROPA have
investigated the additional effects of ACE inhibitors and
have established that ACE inhibitors have additional effects
beyond the blood pressure reduction alone, such as the
improvement of endothelial function, improvement of the
neurohumoral balance, and reduction of unfavourable
remodelling of the coronary arteries [30, 31].
Potential mechanisms of the pharmacogenetic profile
of treatment benefit
In summary, the PERGENE study identified new genetic
determinants of clinical treatment benefit of ACE inhib-
itors, but these genetic determinants do not mediate these
effects through change in BP as these SNPs did not pop up
in the analysis on BP reduction [26, 27]. The treatment
effect modifying SNPs was particularly located in the AT1
and BK1 receptors. The SNPs in the AT1 receptor were
located in the promoter (rs275651) and exon 4 (rs5182) on
chromosome 3, the SNP in the BK1 receptor gene on
chromosome 14 was located in an intron region. All three
SNPs were important tagging SNPs within their candidate
gene [26]. Functionality of these SNPs is at this moment
unknown, but more basic research has been started based
on these findings. As the AT1 receptor is involved in the
direct effects of angiotensin II, it can be hypothesised that
genetic variants in the AT1 receptor will influence the
response to an ACE inhibitor. The exact role of the BK1
Fig. 6 Cumulative effects of the identified SNPs on the prevalence of hypertension. OR hypertension. OR odds ratio CI confidence interval.
Adapted with permission from Brugts JJ, et al. J Hypertens. 2011 Mar;29(3);509–19
Neth Heart J (2012) 20:24–32 29receptor, on the other hand, is less well established.
Bradykinin is a potent vasodilator that also induces
antiatherosclerotic and antithrombotic effects, which are
mediated by BK2 receptors. Previous studies indicated that
the clinical benefit of ACE inhibitors depends, at least in
part, on BK2 receptor activation [32]. In the past year, more
data are emerging on the effect of the BK1 receptor, the
effects of which are less well known. BK1 receptors are
weakly expressed under physiological conditions, but are
strongly induced in response to pathological conditions
and/or RAAS blockade [33, 34]. Recent reports indicate that
BK1 receptor deficiency predisposes to atherosclerosis [35]
and kinins and the BK1 receptor plays an important
deleterious role in this process [36]. Interestingly, it has been
suggested that BK1 receptors are directly activated by ACE
inhibitors (thus resulting in an increase in endothelial NO
release, for instance in the heart [37, 38], by which they do
contribute to the cardioprotective beneficial effects of ACE
inhibitors, but this has not been uniformly confirmed by
others [39]. Therefore, a more likely possibility is that the
upregulated BK1 receptors are activated by their endogenous
ligand during ACE inhibition. Such activation results in the
hypotensive [40], cardioprotective [37] and cerebroprotective
[41] effects of kinins, as observed in animals, and one could
speculate that patients with genetic defects in their BK1
receptor display a diminished response to ACE inhibition
with regard to kinins. Indeed, in our study we observed that
especially patients with the minor allele variants of the BK1
receptor were relatively insensitive or resistant to the
beneficial effect of the ACE inhibitor. Clearly, more work
is needed to support this interesting concept.
Still, the lack of a blood pressure related effect of the 3
identified SNPs in the treatment effect analysis suggests a
different pathway of clinical effect [26, 27] and emphasises
more on the bradykinin effects of ACE inhibitors as the
blood pressure independent effects of ACE inhibitors is
often proposed for the BK pathway [11]. Our analyses may
indicate that the up-regulated BK1 receptor in stressed
CAD patients may play an important role in the assumed
pleiotropic effect of ACE inhibitors. Our findings do
support that concept, as it might be speculated that the
genetic defects in the BK1 receptor alter the antiathero-
sclerotic properties of the ACE inhibitor treatment effect
which might be an important cornerstone of the treatment
benefit besides blood pressure lowering.
Clinical implications: pharmacogenetic breakthrough
in the rationale of prescribing medication
The PERGENE study demonstrated a relative resistance to
ACE inhibitors in patients with unfavourable alleles of the
AT1 receptor and BK1 receptor genes. Based on the
PERGENE findings, three out of four patients with stable
CAD (participating in EUROPA) had an enhanced benefit
of ACE inhibitor therapy, and one out of four patients
experienced a markedly diminished benefit of treatment
with perindopril (non-responders, risk score ≥3).
In our pharmacogenetic profile (Table 1)c a t e g o r i e so f
patients with <3 and ≥3 unfavourable alleles, relative risk
reduction was 33% (HR 0.67; 95% CI 0.56–0.79) and +26%
(HR 1.26; 95% CI 0.97–1.67), respectively. Refraining from
treatment with perindopril in this group of patients may
considerably reduce healthcare costs and increase overall
efficacy of the drug.
In the fictive scenario that only patients with <3
unfavourable alleles would have been treated, which
compromises 76.5% of the population, the absolute risk
would be reduced from 11.1% in placebo to 7.5% in
perindopril patients. Likewise, the number needed to treat
would decrease from 50 to 32. Considering the millions of
patients treated with ACE inhibitors, this reduction has
huge clinical implications and fictively demonstrates the
potential of pharmacogenetic profiling of drug response to
antihypertensives.
Feasibility of pharmacogenetic profiling of ACE
inhibitors
The PERGENE study is one of the first pharmacogenetic
analyses within a randomised clinical trial demonstrating the
heterogeneity in treatment benefit of ACE inhibitors. These
promisingresultsindicatethattheconceptofpharmacogenetic
profiling is feasible and should be investigated more. Further
replication must be sought in other cohorts and replicated in
similar patient populations butalsoinpatientsathigherriskof
events. Additionally, other relevant genetic targets need to be
investigatedsuchasgenesinvolvedinthemetabolismofACE
inhibitors, fe CYP450 genes (pharmacokinetics). However,
until now no specific genetic targets for ACE inhibitor
metabolism have been demonstrated.
Table 1 Hazard ratios for the pharmacogenetic risk scores and clinical
treatment benefit of the ACE inhibitor perindopril
Risk scores Number of patients (%) Hazard ratio (95% CI)
<1 3584 0.58 (0.46–0.72)
2 2826 0.81 (0.63–1.03)
≥3 2316 1.26 (0.97–1.67)
Pharmacogenetic profile
<3 6410 0.67 (0.56–0.79)
≥3 2316 1.26 (0.97–1.67)
Overall study 8726 0.80 (0.71–0.91)
30 Neth Heart J (2012) 20:24–32We advocate that future large-scale randomised
clinical trials should also integrate a pharmacogenetic
analysis in their trial design to prospectively test
treatment efficacy in a similar way. Pharmacogenetic
analyses of clinical trials truly open up a perspective to
individualise preventive therapy in patients with cardio-
vascular disease. Physicians will be able to predict the
response to treatment (responders and non-responders)
in advance, before starting prescription. ‘Individualised
therapy’bypharmacogeneticprofilingwillavoidunnecessary
treatment of non-responding patients and considerably reduce
healthcare costs.
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